The US Food and Drug Administration has approved the first drug specifically developed for postpartum depression.
The FDA has given the green light an IV drug called Zulresso. In a company-funded study of new mothers with moderate or severe postpartum depression, half of the women had Zulresso a depression within two and a half days.
Levels of the naturally occurring hormone progesterone may jump to some women after birth. Doctors say the infusion helps restore normal hormone levels and feelings.
Perinatal psychiatrist Dr. Kristina Deligiannidis says: "Unfortunately, many of our antidepressants are helpful in getting symptoms down, but not quite for many people. So this is an important advance for women suffering from postpartum depression due to the rapid onset they are good at for 60 hours after receiving the drug. "
However, the price tag of the fabric is amazing. Sage Therapeutics says Zulresso will cost $ 34,000 without insurance plus the cost of staying in the hospital or infusion center.
Health insurance can help reduce costs, but the amount of coverage will be determined by each insurance company.
Sage Therapeutics also develops another similar treatment in pill form.
"Postpartum depression is a serious condition that, when severe, can be life-threatening," says Dr. Tiffany Farchione from the FDA Division of Psychiatry Products in a statement. "Women may experience thoughts of harming themselves or harming their child."
Postpartum depression affects about 400,000 American women a year.